WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023. SVB Securities Global Biopharma
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-212 for chronic refractory gout. The analyst expects positive top-line data in 1Q23 for SEL-212. While many will likely compare the results to Horizon Therapeutics PLC's (NASDAQ: HZNP) Krystexxa and the various immunomodulating combinations, Canaccord sees SEL-212 as a step ahead in the gout treatmen
Every investor in Selecta Biosciences, Inc. ( NASDAQ:SELB ) should be aware of the most powerful shareholder groups...